Found: 3
Select item for more details and to access through your institution.
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.1086028
- By:
- Publication type:
- Article
A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability.
- Published in:
- Neurological Sciences, 2020, v. 41, n. 12, p. 3779, doi. 10.1007/s10072-020-04718-6
- By:
- Publication type:
- Article
Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study.
- Published in:
- Frontiers in Immunology, 2021, v. 11, p. N.PAG, doi. 10.3389/fimmu.2021.614715
- By:
- Publication type:
- Article